Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft Tissue Sarcomas: Clinical Outcomes and Biological Correlates

CONCLUSIONS: The combination of eribulin and pembrolizumab demonstrated promising activity in LPS and angiosarcoma.PMID:38236580 | DOI:10.1158/1078-0432.CCR-23-2250

Source: Clinical Cancer Research - January 18, 2024 Category: Cancer & Oncology Authors: Candace L Haddox Michael J Nathenson Emanuele Mazzola Jia-Ren Lin Joanna Baginska Allison Nau Jason L Weirather Edwin Choy Adrian Marino-Enriquez Jeffrey A Morgan Gregory M Cote Priscilla Merriam Andrew J Wagner Peter K Sorger Sandro Santagata Suzanne Geo Source Type: research